Document Detail

Resource Use and Cost Implications of Switching Among Warfarin Formulations in Atrial Fibrillation Patients (December).
MedLine Citation:
PMID:  23150608     Owner:  NLM     Status:  Publisher    
BACKGROUND:Despite the uncertainty surrounding the safety of switching warfarin formulations, limited data exist on the resource use and costs associated with this switching pattern.OBJECTIVE:To evaluate health care resource use and costs associated with switching warfarin formulations among patients with atrial fibrillation (AF) in a managed care organization.METHODS:Patients diagnosed with AF (ICD-9 427.31) between July 2004 and August 2008 and who received warfarin therapy were identified in the HealthCore Integrated Research Database and categorized into 3 groups: users of generic warfarin formulations from a single drug manufacturer (generic-only group), users of branded warfarin formulations only (brand-only group), and patients who used generic and branded warfarin therapy interchangeably or who may have used generic drugs from 1 or more manufacturers (generic/brand switching group). Patients were followed 12 months or longer after their index warfarin prescription date to compare all-cause resource use and costs using multivariable regression analysis.RESULTS:The analysis included 12,908 patients: 71.82% were in the generic-only group, 9.61% were in the brand-only group, and 18.57% were in the generic/brand switching group. Patients in the generic/brand switching group were more likely to be hospitalized (relative risk [RR] = 1.43, p < 0.0001) or to use emergency department services (RR = 1.20, p < 0.01), compared to the brand-only users. Hospitalizations were more likely (RR = 1.26, p < 0.001) to occur among generic-only users versus brand-only users. Adjusted mean pharmacy costs per member per month were lower in the generic/brand switching group compared to the brand-only group ($257 vs $273, p = 0.038), but inpatient costs were higher ($1250 vs $972, p < 0.001), resulting in higher ($2125 vs $1847, p < 0.001) total costs. Generic-only users had lower pharmacy costs compared to brand-only users ($246 vs $273, p < 0.001), but total health care costs trended to be higher in the generic-only group ($1957 vs $1847, p = 0.053).CONCLUSIONS:The use of both generic and branded formulations of warfarin interchangeably, or the use of generics from more than 1 manufacturer, was associated with increased use of all-cause health care resources and total costs in patients with AF.
Winghan Jacqueline Kwong; Siddhesh Kamat; Christy Fang
Related Documents :
35428 - An antacid comparison trial.
8336588 - Nausea, abdominal pain and diarrhoea of uncertain cause responding to ondansetron.
23804318 - Comparison of abluminal biodegradable polymer biolimus-eluting stents and durable polym...
2980548 - Cervical myelography with iohexol and metrizamide. a randomized double blind clinical s...
16086558 - Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow ce...
20207728 - Recovery of pituitary function in the late-postoperative phase after pituitary surgery:...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-13
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  -     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
< Daiichi Sankyo Inc., Parsippany,NJ.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Genetic variants contribute to gene expression variability in humans.
Next Document:  Suboptimal access to primary healthcare among street-based sex workers in southwest Switzerland.